Donepezil Hydrochloride Torrent Pharma (Uk) (Donepezil Hydrochloride)

Donepezil Hydrochloride is indicated for the management of cognitive symptoms associated with Alzheimer’s disease.

• Improves memory and attention in patients with mild to moderate Alzheimer’s disease.
• Supports daily functioning by enhancing cholinergic neurotransmission.
• Used as part of a comprehensive care plan that includes non‑pharmacologic interventions.
• May be considered when other cholinesterase inhibitors are not tolerated.
• Prescribed by a qualified healthcare professional after diagnosis confirmation.

Side effects of Donepezil Hydrochloride can vary in frequency and severity; they are typically reported during the first weeks of therapy.

Common

• Nausea or vomiting.
• Diarrhea or abdominal discomfort.
• Insomnia or vivid dreams.
• Muscle cramps or weakness.
• Fatigue or decreased energy.
• Loss of appetite.

Serious

• Bradycardia or heart block.
• Severe allergic reactions such as rash, swelling, or difficulty breathing.
• Hepatic dysfunction indicated by jaundice or abnormal liver tests.
• Seizures or convulsions.
• Persistent dizziness leading to falls.

When prescribing Donepezil Hydrochloride, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess cardiac history, especially bradyarrhythmias or sick sinus syndrome.
• Review concurrent use of other cholinergic or anticholinergic agents.
• Monitor liver function in patients with hepatic impairment.
• Use caution in patients with asthma or chronic obstructive pulmonary disease.
• Evaluate renal function, although dose adjustment is rarely required.
• Consider pregnancy and breastfeeding status; safety data are limited.
• Counsel patients on the potential for gastrointestinal upset and advise taking the medication with food if needed.

Donepezil Hydrochloride may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole).
• Co‑administration with anticholinergic drugs that may reduce therapeutic efficacy.
• Use with other acetylcholinesterase inhibitors.

Use with caution

• Beta‑blockers or calcium channel blockers due to additive bradycardia risk.
• NSAIDs or anticoagulants because of potential gastrointestinal bleeding.
• Drugs that affect cardiac conduction such as digoxin.